Board of Directors
Jacques Bojin, Chairman of the Board
Jacques Bojin was elected Chairman of the Board in July 2006.
Prior to his involvement with ScreenCell, Bojin was a Management Consultant specialized in Corporate Strategy and his clients were mostly large international companies in the health and pharmaceutical industries.
He started his consulting career with McKinsey & Company, then became Chairman and CEO of The ABC Group, an international strategy consulting firm, and of its main subsidiary, DEF International, specialized in Management Training. He also served as President and CEO of The Terrin Group, the second largest ship-repair yard in Europe and was a director of several pharmaceutical and cosmetics firms.
Trained as a Mechanical Engineer at École des Arts & Métiers Paris Tech in Paris, France, he also received a MA in Economics from Institut d’Études Poitiques in Paris and an SM in Management from the MIT Sloan School.
Ian Jones, Vice-Chairman of the Board
Ian Jones is the founder and general manager of Array Genomics, a company he created in 2002, which is specialized in innovative, non-invasive tests to detect cancer pathologies and various genetic anomalies.
Previously, he was Vice-President in charge of Business Development à Vysis SA.
Jones holds a B.Sc. in Business Studies from the London Business School.
Sophie Pierrin-Lépinard, Member, representing Banexi Ventures Partners
Sophie Pierrin-Lépinard is a General Partner at Banexi Ventures Partners, the leading stockholder in ScreenCell, where she is in charge of investments in the Healthcare sector.
She began her career in marketing at Procter & Gamble Pharmaceuticals, before becoming an investment manager in the venture capital branch of Crédit Agricole in Paris and joined Banexi Ventures Partners in 1995.
She has invested in more than 20 companies in the healthcare sector including Genset (listed on Paris Eurolist and then acquired by Serono), CV Therapeutics (listed on the Nasdaq) or Nale (merger with Warner Chilcott and then listed on the Nasdaq), Exonhit Therapeutics (listed on Paris Alternext in 2005). Her current portfolio includes Vexim, Screencell, Roowin & Symetis.
Pierrin holds a Ph.D in Pharmacy from Toulouse University and an MA in Finance from École Supérieure de Commerce in Paris.